The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.
Why Is Passage Bio, Inc. (PASG) Stock Down Today?
Updated Nov 16, 2026 5:42 PM ET · Prev Close $4.25
Session Regime & Catalyst Assessment
68% Signal ConvictionPassage Bio, Inc. Pulling Back 2.82% on 1.12x Relative Volume
Passage Bio, Inc. (PASG) is pulling back 2.82% (-$0.12) to $4.13 on 1.12x average session volume. Relative to benchmarks, PASG is lagging the S&P 500 by -0.91%. 14-day RSI stands at 57.0, keeping momentum in a bullish regime.
The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.
Price ($4.13) holds above both 20-day ($3.62) and 50-day ($4.10) moving averages.
Market & Sector Relative Strength
PASG lagging the S&P 500 by -0.91%Recent PASG Catalyst Headlines
Verified WireThe after-hours decline was driven by concerns over trading activity, business performance and company restructuring plans.
Passage Bio said on Wednesday that it will merge with privately held Remix Therapeutics.
Combined company to operate as Remix Therapeutics and advance Remix s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix s lead program, REM-
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $4.10 (50-day SMA support) for directional breakout confirmation.
Technical Regime (PASG)
MIXED MA TRENDRetail & Crowd Sentiment
NeutralPassage Bio signed an all-stock merger deal with Remix Therapeutics, but the stock price dropped significantly after hours despite the bullish news.
About Passage Bio, Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative …
Get Instant PASG Catalyst Alerts
Receive an email alert when PASG triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversPASG Session & Catalyst FAQ
Why is PASG stock down today?
Passage Bio, Inc. (PASG) is pulling back 2.82% (-$0.12) to $4.13 on 1.12x average session volume. Relative to benchmarks, PASG is lagging the S&P 500 by -0.91%. 14-day RSI stands at 57.0, keeping momentum in a bullish regime.
Is PASG stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.12x relative volume (moderate participation). Our multi-factor model currently rates PASG as STRONG SELL. Review full valuation, quality, and timing signals on the PASG Buy or Sell Decision Brief →
What is PASG's intrinsic value and expected trading range?
At $4.13, PASG's modeled 1-to-3 session range is $3.90 – $4.36, with a key inflection level at $4.10 (50-day SMA support). Compare current price against multi-year cash flow projections in the PASG Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for PASG?
RSI at 57.0 reflects constructive bullish momentum. PASG trades at $4.13 relative to its 20-day SMA ($3.62) and 50-day SMA ($4.10), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.